Company news

Neuren Pharmaceuticals Limited news in 2022

Neuren Pharmaceuticals Limited's news releases, calls and decks from 2022, newest first.

View company

Neuren submits IND & first patients complete Phase 2 trials

December 22, 2022

Q3 2022 quarterly activity and cash flow report

October 26, 2022

Neuren receives US$10 million milestone payment

October 19, 2022

Rett Syndrome NDA accepted for Priority Review by FDA

September 12, 2022

S&P DJI Announces September 2022 Quarterly Rebalance

September 2, 2022

Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS

August 7, 2022

Quarterly Activities/Appendix 4C Cash Flow Report

July 29, 2022

Acadia submits Rett Syndrome New Drug Application to the FDA

July 19, 2022

Neuren commences Phase 2 trial of NNZ-2591 in Angelman

July 11, 2022

Neuren appoints Chief Medical Officer in United States

July 8, 2022

FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial

March 24, 2022

FDA approval for Phelan-McDermid IND and Phase 2 trial

March 22, 2022

Ethics approval for Angelman Phase 2 trial in Australia

March 10, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

FDA approval for Angelman IND and Phase 2 trial

February 24, 2022

2021 Results - a transformational year for Neuren

February 23, 2022

Preliminary Final Report and 2021 Full Year Accounts

February 23, 2022

Notification regarding unquoted securities - NEU

February 3, 2022

Q4 2021 quarterly activity and cash flow report

January 30, 2022

Decks in 2022